Showing results (541-550 of 585) with videos related to

Sort By:
Pageof 59
Journal of Gastroenterology and Hepatology|January 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCCTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2023
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Reports (Hoboken, N.J.)|April 5, 2024
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancers|September 9, 2023
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective StudyKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Oncology|February 3, 2025
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not SufficientAtsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 14, 2025
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter studyAtsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and BevacizumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2025
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre StudyTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Pageof 59